Hiroyuki Tsuchie1, Makoto Emori2, Naohisa Miyakoshi3, Hiroyuki Nagasawa3, Kyoji Okada4, Hiroshi Nanjyo5, Yasutaka Murahashi2, Emi Mizushima2, Junya Shimizu2, Toshihiko Yamashita2, Yoichi Shimada3. 1. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan tuchikiti@yahoo.co.jp. 2. Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan. 3. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan. 4. Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan. 5. Department of Pathology, Akita University Graduate School of Medicine, Akita, Japan.
Abstract
BACKGROUND/AIM: Abnormal expression of CD44 may promote cancer invasion. However, a limited number of studies have investigated the expression of CD44 in soft tissue sarcoma such as myxofibrosarcoma. We evaluated the relationship between expression of the standard form of CD44 (CD44s) and the clinical course of myxofibrosarcoma. MATERIALS AND METHODS: Forty-four myxofibrosarcoma patients were retrospectively enrolled. Patient information including the proportion of CD44s-positive cells was collected, and multivariate analyses were conducted to determine the relationship between CD44s expression and clinicopathological factors. RESULTS: Although CD44s did not affect prognosis, multivariate analysis indicated that high expression of CD44s predicted poor event-free survival (p=0.004) and local recurrence (p=0.049). CD44s expression was not associated with the occurrence of distant metastasis but was significantly higher in those with lung metastasis (p=0.044). CONCLUSION: Increased expression of CD44s predicted poor event-free survival and local recurrence and was observed in myxofibrosarcoma patients with lung metastasis. Copyright
BACKGROUND/AIM: Abnormal expression of CD44 may promote cancer invasion. However, a limited number of studies have investigated the expression of CD44 in soft tissue sarcoma such as myxofibrosarcoma. We evaluated the relationship between expression of the standard form of CD44 (CD44s) and the clinical course of myxofibrosarcoma. MATERIALS AND METHODS: Forty-four myxofibrosarcoma patients were retrospectively enrolled. Patient information including the proportion of CD44s-positive cells was collected, and multivariate analyses were conducted to determine the relationship between CD44s expression and clinicopathological factors. RESULTS: Although CD44s did not affect prognosis, multivariate analysis indicated that high expression of CD44s predicted poor event-free survival (p=0.004) and local recurrence (p=0.049). CD44s expression was not associated with the occurrence of distant metastasis but was significantly higher in those with lung metastasis (p=0.044). CONCLUSION: Increased expression of CD44s predicted poor event-free survival and local recurrence and was observed in myxofibrosarcoma patients with lung metastasis. Copyright
Authors: Jacob Engellau; Pär-Ola Bendahl; Annette Persson; Henryk A Domanski; Måns Akerman; Pelle Gustafson; Thor A Alvegård; Mef Nilbert; Anders Rydholm Journal: Hum Pathol Date: 2005-09 Impact factor: 3.466
Authors: Roberta Sanfilippo; Rosalba Miceli; Federica Grosso; Marco Fiore; Elisa Puma; Elisabetta Pennacchioli; Marta Barisella; Claudia Sangalli; Luigi Mariani; Paolo G Casali; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2010-09-28 Impact factor: 5.344
Authors: Ana Gvozdenovic; Matthias J E Arlt; Carmen Campanile; Patrick Brennecke; Knut Husmann; Yufei Li; Walter Born; Roman Muff; Bruno Fuchs Journal: J Bone Miner Res Date: 2013-04 Impact factor: 6.741
Authors: G Petur Nielsen; John T Mullen; Nicole J Look Hong; Francis J Hornicek; Kevin A Raskin; Sam S Yoon; Jackie Szymonifka; Beow Yeap; Yen-Lin Chen; Thomas F DeLaney Journal: Ann Surg Oncol Date: 2012-08-14 Impact factor: 5.344
Authors: Christiane Matuschek; Marcus Lehnhardt; Peter Arne Gerber; Christopher Poremba; Jackson Hamilton; Guido Lammering; Klaus Orth; Wilfried Budach; Hans Bojar; Edwin Bölke; Matthias Peiper Journal: Eur J Med Res Date: 2014-02-03 Impact factor: 2.175